KINNATE BIOPHARMA INC's ticker is KNTE and the CUSIP is 49705R105. A total of 60 filers reported holding KINNATE BIOPHARMA INC in Q3 2023. The put-call ratio across all filers is 0.76 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,141,990 | -53.8% | 815,707 | 0.0% | 0.08% | -56.0% |
| Q2 2023 | $2,471,592 | -51.5% | 815,707 | 0.0% | 0.19% | -43.2% |
| Q1 2023 | $5,098,169 | +2.5% | 815,707 | 0.0% | 0.34% | +8.0% |
| Q4 2022 | $4,975,813 | -49.0% | 815,707 | 0.0% | 0.31% | -33.1% |
| Q3 2022 | $9,748,000 | -5.2% | 815,707 | 0.0% | 0.46% | -8.3% |
| Q2 2022 | $10,286,000 | +46.3% | 815,707 | +30.7% | 0.51% | +36.7% |
| Q1 2022 | $7,029,000 | -28.3% | 624,236 | +12.9% | 0.37% | -20.0% |
| Q4 2021 | $9,801,000 | -14.6% | 553,128 | +11.0% | 0.46% | -21.9% |
| Q3 2021 | $11,476,000 | +64.3% | 498,528 | +66.2% | 0.59% | +91.6% |
| Q2 2021 | $6,984,000 | -25.3% | 300,000 | 0.0% | 0.31% | -19.7% |
| Q1 2021 | $9,348,000 | -21.7% | 300,000 | 0.0% | 0.39% | -24.6% |
| Q4 2020 | $11,934,000 | – | 300,000 | – | 0.51% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 9,671,643 | $60,447,769 | 31.36% |
| Vida Ventures Advisors, LLC | 2,207,772 | $13,798,575 | 18.88% |
| Lynx1 Capital Management LP | 2,214,250 | $13,839,063 | 11.54% |
| Foresite Capital Management V, LLC | 1,975,001 | $12,343,756 | 9.12% |
| Nextech Invest Ltd. | 2,329,480 | $14,559,250 | 6.08% |
| Ally Bridge Group (NY) LLC | 109,393 | $683,706 | 0.90% |
| Orbimed Advisors | 5,143,629 | $32,147,681 | 0.63% |
| RA Capital Management | 4,264,144 | $26,650,900 | 0.60% |
| Novo Holdings A/S | 815,707 | $5,098,169 | 0.34% |
| HARVARD MANAGEMENT CO INC | 498,001 | $3,112,506 | 0.33% |